EVMN
Evommune, Inc.Company Information
- Company Name
- Evommune, Inc.
- CIK
- CIK0002044725
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- EVMN: NYSE
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- EVMN
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-07-08
- Last sale
- 2026-06-22
- Shares purchased (TTM)
- 4,387,000
- Shares sold (TTM)
- 100,854
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 32,769,434
- Shares outstanding
- 36,135,644
- Ownership
- 90.68%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- -1.12%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||
| Cash And Cash Equivalents At Carrying Value | 60 | 48 | 44 | 27 | ||||||
| Short Term Investments | 141 | 163 | 105 | 49 | ||||||
| Prepaid Expense And Other Assets Current | 3 | 4 | 4 | 6 | ||||||
| Assets Current | 204 | 216 | 153 | 82 | ||||||
| Operating Lease Right Of Use Asset | 8 | 8 | 1 | 0 | ||||||
| Property Plant And Equipment Net | 2 | 2 | 1 | 1 | ||||||
| Long Term Investments | 87 | 96 | 67 | - | ||||||
| Restricted Cash Noncurrent | 1 | 1 | 1 | 1 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | ||||||
| Assets | 302 | 322 | 225 | 85 | ||||||
Liabilities Current | ||||||||||
| Accounts Payable Current | 5 | 4 | 8 | 4 | ||||||
| Accrued Liabilities Current | 11 | 5 | 10 | 6 | ||||||
| Operating Lease Liability Current | 1 | 1 | 0 | 0 | ||||||
| Other Liabilities Current | 1 | 1 | 0 | 0 | ||||||
| Liabilities Current | 17 | 11 | 18 | 10 | ||||||
| Other Liabilities Noncurrent | - | - | - | 0 | ||||||
| Operating Lease Liability Noncurrent | 6 | 7 | 1 | - | ||||||
| Finance Lease Liability Noncurrent | 0 | 1 | 0 | - | ||||||
| Liabilities | 24 | 18 | 19 | 11 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | - | 0 | 257 | ||||||
Stockholders Equity | ||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 553 | 547 | 427 | 10 | ||||||
| Retained Earnings Accumulated Deficit | -275 | -243 | -221 | -193 | ||||||
| Stockholders Equity | 278 | 305 | 206 | -183 | ||||||
| Liabilities And Stockholders Equity | 302 | 322 | 225 | 85 | ||||||
| Temporary Equity Par Or Stated Value Per Share | - | - | 0.00 | 0.00 | ||||||
| Temporary Equity Shares Authorized | - | - | 10 | 158 | ||||||
| Temporary Equity Shares Issued | - | - | 0 | 158 | ||||||
| Temporary Equity Shares Outstanding | - | - | 0 | 158 | ||||||
| Temporary Equity Liquidation Preference | - | - | 0 | 276 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 224 | ||||||
| Common Stock Shares Issued | 36 | 36 | 32 | 2 | ||||||
| Shares Outstanding | 36 | 36 | 32 | 2 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialEvommune, Inc. (EVMN) — SEC Financial Statements & Analysis
Evommune, Inc. (EVMN) is a pharmaceutical preparations company, incorporated in DE. Evommune, Inc. trades on NYSE as: EVMN. Evommune, Inc. (EVMN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Evommune, Inc. carries a market cap of $480.24M, a P/E ratio of -3.91x, a P/B ratio of 1.73x, a P/S ratio of 36.94x, an enterprise value of $419.44M, and an EV/EBITDA multiple of -3.05x. On profitability, it posts an operating margin of -1076.31%, a net margin of -944.54%, a Return on Equity (ROE) of -44.23%, a Return on Assets (ROA) of -40.67%, and a Return on Invested Capital (ROIC) of -64.47%. Per share, it reports EPS of $-3.40, diluted EPS of $-3.40, free cash flow per share of $-3.45, and a dividend per share of $0.00. On the balance sheet, it maintains a current ratio of 11.68x, a quick ratio of 11.48x, working capital of $186.76M, a debt-to-equity ratio of 0.09x, a debt ratio of 0.08, free cash flow of $-124.76M (TTM), and net debt of $-60.80M. Figures sourced from SEC EDGAR.
- Market Cap
- $480.24M
- P/E TTM
- -3.91x
- EPS TTM
- $-3.40
- P/B TTM
- 1.73x
- ROE TTM
- -44.23%
- ROA TTM
- -40.67%
- Debt To Equity
- 0.09x
- Free Cash Flow TTM
- $-124.76M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Evommune, Inc. in?
Evommune, Inc. (EVMN) operates in the Pharmaceutical Preparations industry.
What exchange does EVMN trade on?
Evommune, Inc. (EVMN) trades on the NYSE.
Where is Evommune, Inc. incorporated?
Evommune, Inc. is incorporated in DE.
When was Evommune, Inc. (EVMN)'s most recent SEC filing?
Evommune, Inc. (EVMN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is EVMN's market cap?
Evommune, Inc. (EVMN) has a market capitalization of $480.24M as of 2026-06-30.
What is EVMN's EPS (earnings per share)?
Evommune, Inc. (EVMN)'s trailing twelve month EPS is $-3.40 as of 2026-06-30.
What is EVMN's ROE (return on equity)?
Evommune, Inc. (EVMN)'s trailing twelve month Return on Equity (ROE) is -44.23% as of 2026-06-30.
What is EVMN's ROA (return on assets)?
Evommune, Inc. (EVMN)'s trailing twelve month Return on Assets (ROA) is -40.67% as of 2026-06-30.
What is EVMN's ROIC (return on invested capital)?
Evommune, Inc. (EVMN)'s trailing twelve month Return on Invested Capital (ROIC) is -64.47% as of 2026-06-30.
What is EVMN's EV/EBITDA?
Evommune, Inc. (EVMN)'s trailing twelve month EV/EBITDA is -3.05x as of 2026-06-30.